Long-term efficacy and safety results (60 weeks) of a double-blind, placebo-controlled, crossover trial of infliximab for patients with moderate to severe hidradenitis suppurativa

被引：0
|
作者：
Grant, A. [1 ]
Kerdel, F. A. [1 ]
Gonzalez, T. [2 ]
机构：
[1] Florida Acad Dermatol Ctr, Miami, FL USA
[2] Centocor Inc, Horsham, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2009年 / 60卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB106 / AB106
页数：1
相关论文
共 50 条
  • [1] A double-blind, placebo-controlled, crossover trial to assess the efficacy and safety of infliximab for patients with moderate to severe hidradenitis suppurativa
    Grant, Annika
    Gonzalez, T.
    Kerdel, E. A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB38 - AB38
  • [2] Infliximab therapy for patients with moderate to severe hidradenitis, suppurativa: A randomized, double-blind, placebo-controlled crossover trial
    Grant, Annika
    Gonzalez, Tayler
    Montgomery, Michael O.
    Cardenas, Vanessa
    Kerdel, Francisco A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (02) : 205 - 217
  • [3] Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
    Glatt, Sophie
    Jemec, Gregor B. E.
    Forman, Seth
    Sayed, Christopher
    Schmieder, George
    Weisman, Jamie
    Rolleri, Robert
    Seegobin, Seth
    Baeten, Dominique
    Ionescu, Lucian
    Zouboulis, Christos C.
    Shaw, Stevan
    [J]. JAMA DERMATOLOGY, 2021, 157 (11) : 1279 - 1288
  • [4] A LONG-TERM, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF THE EFFICACY OF FLUOXETINE FOR TRICHOTILLOMANIA
    STREICHENWEIN, SM
    THORNBY, JI
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (08): : 1192 - 1196
  • [5] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: Results from the placebo-controlled portion of a phase II, randomized, double-blind study
    Kimball, A.
    Jemec, G.
    Okun, M.
    Gu, Y.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB155 - AB155
  • [6] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo-controlled portion of a phase II, randomized, double-blind study
    Kimball, A. B.
    Jemec, G.
    Gu, Y.
    Okun, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 6 - 6
  • [7] A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
    Miller, I.
    Lynggaard, C. D.
    Lophaven, S.
    Zachariae, C.
    Dufour, D. N.
    Jemec, G. B. E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (02) : 391 - 398
  • [8] Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial (vol 157, pg 1279, 2021)
    Terlizzi, Joseph P.
    Baker, Jonathan
    Goldstone, Stephen E.
    [J]. JAMA DERMATOLOGY, 2021, 157 (11) : 1384 - 1384
  • [9] Safety and efficacy of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial
    Herra, L. Escudero
    Kimball, A.
    Zouboulis, C. C.
    Armstrong, A. W.
    Korman, N. J.
    Crowley, J. J.
    Lynde, C.
    Belknap, K.
    Gu, Y.
    Williams, D. A.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 34 - 34
  • [10] Safety and efficacy of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial
    Kimball, Alexa
    Zouboulis, Christos
    Armstrong, April
    Korman, Neil
    Crowley, Jeffrey
    Lynde, Charles
    Belknap, Kimberly
    Gu, Yihua
    Williams, David
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB60 - AB60
12345